EMAIL THIS PAGE TO A FRIEND

Gastroenterology

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.


PMID 25160979

Abstract

Noninvasive surrogate end points of long-term outcomes of patients with primary biliary cirrhosis (PBC) are needed to monitor disease progression and evaluate potential treatments. We performed a meta-analysis of individual patient data from cohort studies to evaluate whether patients' levels of alkaline phosphatase and bilirubin correlate with their outcomes and can be used as surrogate end points. We performed a meta-analysis of data from 4845 patients included in 15 North American and European long-term follow-up cohort studies. Levels of alkaline phosphatase and bilirubin were analyzed in different settings and subpopulations at different time points relative to the clinical end point (liver transplantation or death). Of the 4845 patients, 1118 reached a clinical end point. The median follow-up period was 7.3 years; 77% survived for 10 years after study enrollment. Levels of alkaline phosphatase and bilirubin measured at study enrollment (baseline) and each year for 5 years were strongly associated with clinical outcomes (lower levels were associated with longer transplant-free survival). At 1 year after study enrollment, levels of alkaline phosphatase that were 2.0 times the upper limit of normal (ULN) best predicted patient outcome (C statistic, 0.71) but not significantly better than other thresholds. Of patients with alkaline phosphatase levels ≤ 2.0 times the ULN, 84% survived for 10 years compared with 62% of those with levels >2.0 times the ULN (P < .0001). Absolute levels of alkaline phosphatase 1 year after study enrollment predicted patient outcomes better than percentage change in level. One year after study enrollment, a bilirubin level 1.0 times the ULN best predicted patient transplant-free survival (C statistic, 0.79). Of patients with bilirubin levels ≤ 1.0 times the ULN, 86% survived for 10 years after study enrollment compared with 41% of those with levels >1.0 times the ULN (P < .0001). Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times. We confirmed the predictive value of alkaline phosphatase and bilirubin levels in multiple subgroups, such as patients who had not received treatment with ursodeoxycholic acid, and at different time points after study enrollment. Levels of alkaline phosphatase and bilirubin can predict outcomes (liver transplantation or death) of patients with PBC and might be used as surrogate end points in therapy trials.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P8361 Phosphatase, Alkaline bovine, recombinant, expressed in Pichia pastoris, ≥4000 units/mg protein
P0114
Phosphatase, Alkaline from bovine intestinal mucosa, BioUltra, buffered aqueous glycerol solution, ≥6,500 DEA units/mg protein
A2356
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥5,500 DEA units/mg protein
P7923
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥4,000 DEA units/mg protein
P6774
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous solution, 2,000-4,000 DEA units/mg protein
P5521
Phosphatase, Alkaline from bovine intestinal mucosa, ≥2,000 DEA units/mg protein
P7640
Phosphatase, Alkaline from bovine intestinal mucosa, lyophilized powder, ≥10 DEA units/mg solid
P4653
Phosphatase, Alkaline from bovine kidney, lyophilized powder, ≥5 units/mg protein (Activity determined in diethanolamine buffer, pH 9.8)
P4978 Phosphatase, Alkaline from calf intestine, buffered aqueous glycerol solution
P4252 Phosphatase, Alkaline from Escherichia coli, ammonium sulfate suspension, 30-90 units/mg protein (modified Warburg-Christian, in glycine buffer)
P4069 Phosphatase, Alkaline from Escherichia coli, buffered aqueous glycerol solution, 20-50 units/mg protein (in glycine buffer)
P5931 Phosphatase, Alkaline from Escherichia coli, lyophilized powder, 30-60 units/mg protein (in glycine buffer)
P3895 Phosphatase, Alkaline from human placenta, ≥10 units/mg solid (in glycine buffer)
P4002 Phosphatase, Alkaline from porcine intestinal mucosa, ≥1 unit/mg solid (in glycine buffer)
P4439 Phosphatase, Alkaline from porcine kidney, lyophilized powder, ≥100 DEA units/mg protein
P2265 Phosphatase, Alkaline from rabbit intestine, 0.2-0.6 unit/mg solid (in glycine buffer)
A2237 Phosphatase, Alkaline shrimp, ≥1,000 DEA units/mL, buffered aqueous glycerol solution, recombinant, expressed in proprietary host
U5127
Ursodeoxycholic acid, ≥99%
C24H40O4
U0800000
Ursodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
C24H40O4
Y0001163
Ursodeoxycholic acid for system suitability, European Pharmacopoeia (EP) Reference Standard
C24H40O4
1707806
Ursodiol, United States Pharmacopeia (USP) Reference Standard
C24H40O4